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Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease with a 5-year survival of 4%. 
A key hallmark of PDAC is extensive stromal involvement, which makes capturing precise tumor-
specific molecular information difficult. Here, we have overcome this problem by applying blind 
source separation to a diverse collection of PDAC gene expression microarray data, which 
includes primary, metastatic, and normal samples. By digitally separating tumor, stroma, and 
normal gene expression, we have identified and validated two tumor-specific subtypes including a 
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“basal-like” subtype which has worse outcome, and is molecularly similar to basal tumors in 
bladder and breast cancer. Furthermore, we define “normal” and “activated” stromal subtypes 
which are independently prognostic. Our results provide new insight into the molecular 
composition of PDAC which may be used to tailor therapies or provide decision support in a 
clinical setting where the choice and timing of therapies is critical.
Rigorous sequencing studies have shown that few genetic alterations (KRAS, CDKN2A, 
SMAD4, and TP53) are prevalent in PDAC1-3, but these and other analyses of PDAC tumors 
are hampered by limited tumor cellularity and the presence of abundant stroma intermixed 
with normal endocrine and exocrine cells. Additionally, metastatic samples often include 
cell types from the host organ. Thus, PDAC tumors are complex mixtures in which the 
malignant epithelial cells often represent a minority of the tissue compartment (Fig. 1a). 
Illustrating this limitation, an important study of exome and copy number in pancreatic 
cancer removed 43 of 142 patients due to low tumor cellularity affecting the sensitivity of 
mutation detection1. While some studies use microdissection to improve tumor content4-7, 
microdissection for precision medicine approaches is not yet feasible. When considering 
gene expression of bulk tumors, normal pancreas and PDAC tissues often cluster together, 
separate from cell lines which are assumed to be purely neoplastic8.
Separating molecular signatures of tissue compartments from the measurements of bulk 
tumor belongs to the general class of problems called blind source separation. Previous 
studies have used samples of chronic pancreatitis, which is often fibrotic, to control for the 
presence of desmoplastic stroma in tumor samples9. In prostate cancer, Stuart et al. have 
used pathology assessments of cell types to train models of gene expression signatures of 
tumor, stroma, and normal tissue10. In a follow up study, they used their learned gene lists 
for in silico estimation of tissue components in a larger set of data11. A similar approach has 
also been used to quantify stromal content across multiple data sets from the cancer genome 
atlas (TCGA)12. Among source separation techniques, nonnegative matrix factorization 
(NMF) is especially well suited for biological data, because it constrains all sources to be 
positive in nature, reflecting the goal of identifying positive gene expression exemplars, 
rather than pairwise differences between tissue types. Briefly, we define NMF as modeling 
the matrix X of expression for g genes and s samples, as the product of a matrix G of g gene 
weights for k factors and a matrix S of s sample weights for k factors. Alexandrov et al. have 
recently demonstrated that NMF is useful for a similar problem of identifying mutational 
signatures from the aggregate list of somatic mutations in human cancer samples13,14. 
Similarly, Biton et al. have applied a related technique, Independent component analysis, to 
examine gene expression in bladder cancer15.
In this study, we have overcome the challenges of bulk tumor analysis where signal is 
averaged out between normal, tumor and stroma compartments, by using NMF to perform a 
virtual microdissection of primary and metastatic PDAC samples. This has allowed us to 
identify tumor-specific and stroma-specific subtypes with prognostic and biologic relevance. 
In addition, by focusing on tumor autonomous gene expression, we found that intra-patient 
tumor heterogeneity between primary and metastatic sites was unexpectedly low.
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Virtual microdissection of PDAC
We used NMF to analyze gene expression in a cohort of microarray data from 145 primary 
and 61 metastatic PDAC tumors, 17 cell lines, 46 pancreas and 88 distant site adjacent 
normal samples using Agilent (Agilent Technologies) human whole genome 4x44K DNA 
microarrays (106 primary tumors were previously used in a separate bulk analysis of gene 
expression (GSE2150116). To validate our findings, RNA sequencing was performed on 15 
primary tumors, 37 pancreatic cancer patient-derived xenografts (PDX), 3 cell lines, and 6 
cancer associated fibroblast (CAF) lines derived from deidentified patients with pancreatic 
cancer. Histology of all available samples was reviewed by a single blinded pathologist 
(KEV). Table 1 summarizes the demographic and clinical characteristics of patients in our 
cohorts.
NMF distinguishes normal and tumor compartments
A key obstacle in the analysis of gene expression data, particularly in PDAC, is the removal 
of confounding normal or stroma gene expression from local and distant organ sites. 
Supplementary Figure 1 shows example histology of samples with both tumor, normal, and 
stromal tissue. We used NMF to identify gene expression which we attribute to normal 
pancreas, liver, lung, muscle, and immune tissues. Expression of exemplar genes from these 
factors, i.e. genes with distinctly large weights in a single column of G, as well as factor 
weights for the samples, i.e. rows of S, showed excellent agreement with known tissue labels 
(Fig. 1b, c, Supplementary Fig. 2). Investigation of the exemplar genes from these factors 
further confirmed their role as confounding normal tissue. For example, using the 
Kolmogorov–Smirnov test, the top-weighted genes from the liver factor show significant 
(p<10-10) enrichment in the MSigDB term SU_LIVER (Supplementary table 1), and the 
highest weighted gene, fibrinogen beta (FGB) (Supplementary table 2), is specifically 
expressed in normal human liver tissue.
In addition to normal tissue from distant organs, we found two factors which were exclusive 
to pancreas tissue, but were differentiated from each other by their respective gene lists. One 
factor described endocrine function including expression of glucagon and insulin (GCG and 
INS) (Supplementary table 2), while the other factor described exocrine function including 
expression of digestive enzyme genes such as pancreatic lipase, PNLIP (Supplementary 
table 2). This unsupervised discovery of two molecularly distinct yet highly co-localized 
factors related to normal pancreatic function represents an important proof of concept in the 
use of NMF to identify novel features without pre-defined expression knowledge.
To validate our normal expression signatures, all available samples were reviewed by a 
single pathologist (KEV) to independently assess the amount of tumor, normal, and stroma 
cellularity. We found that many factor weights were correlated or anti-correlated to tumor 
cellularity (Supplementary Fig. 3). Among normal and metastatic liver samples, for 
example, tumor-specific factor weights were correlated with cellularity whereas the normal-
specific liver factor weight was inversely related to the tumor content of a sample (Fig. 1d). 
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These findings support our hypothesis that factor weights obtained from NMF are 
quantitatively indicative of underlying sample composition.
Identification of stroma-specific subtypes
Stroma is particularly important in PDAC. According to pathology assessments, stroma 
varies (Supplementary Fig. 1 c-e), and comprises on average 48% of our primary tumor 
samples with a standard deviation of 30%. Our analysis identified two factors, which 
describe gene expression from the stroma, which were distinctly different from the normal 
factors shown in Figure 1. Consensus clustering on exemplar genes from these two stroma 
factors divided tumor samples into two stromal subtypes, which we classified as “normal”, 
and “activated” (Fig. 2a). Patients with samples with an activated stroma subtype had worse 
median survival of 15 months and 60% 1-year survival when compared to patients with a 
normal stroma subtype (median 24 months, 1-year 82%, Fig. 2b). Both were notably absent 
in PDAC cell lines (Fig. 2c), which exhibited a distinct mitotic expression signature 
associated with mitotic checkpoints and DNA replication (Supplementary table 1)17. The 
fact that cell lines do not express these stromal factors, and that many metastatic samples 
express them at low levels (Supplementary Fig. 4), suggest that these genes are not 
expressed by the tumor epithelium. To further validate the stromal origin of these gene 
expression signatures, we isolated 6 CAF lines from primary tumors (Supplementary Fig. 5), 
and found that they robustly overexpressed our hypothesized stromal signatures compared to 
PDAC tumor cell lines which had no expression of the stromal signatures (Fig. 2c).
The vast majority of collagen gene expression was attributable to stromal compartments, 
with the lone exception being COL17A1, which was high in tumors. “Normal” stroma was 
characterized by relatively high expression of known markers for pancreatic stellate cells, 
smooth muscle actin, vimentin, and desmin, (ACTA2, VIM, and DES). Stellate cells have 
been shown to promote cancer cell survival in vitro18, but at the same time may restrain 
PDAC in mouse models19,20. Targeting desmoplastic stroma by hedgehog pathway 
inhibition has been shown to both accelerate the development of disease21 and enhance 
delivery of chemotherapy22. In patients, the ratio of smooth muscle actin stained area to the 
collagen-stained area has been shown to be predictive of poor outcomes23. We found that 
“activated” stroma was characterized by a more diverse set of genes associated with 
macrophages, such as the integrin ITGAM, and the chemokine ligands CCL13 and CCL18. 
“Activated” stroma also expressed other genes which point to its role in tumor promotion, 
including the secreted protein SPARC, WNT family members WNT2, and WNT5A, 
gelatinase B (MMP9), and stromelysin 3 (MMP11). The presence of fibroblast activation 
protein (FAP), which has previously been related to worse prognosis, in the activated stroma 
suggests that an activated fibroblast state may be partially responsible for the poor outcomes 
for these patients24. This lead us to hypothesize that the “normal” stroma factor may 
describe a “good” version of stroma and that “activated” stroma factor may describe the 
activated inflammatory stromal response that has been seen in previous studies to be 
responsible for disease progression25-27. Our factor analysis supports a complex, multi-gene 
model of stroma in PDAC, which may explain why single gene analysis has yielded mixed 
results.
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Identification of tumor-specific subtypes
Independent of normal and stromal factors, we found that two tumor-specific factors define 
“classical” and “basal-like” subtypes of PDAC. When our samples were split into the two 
tumor subtypes (Fig. 3a), patients with basal-like subtype tumors had an overall worse 
median survival of 11 months and 44% 1-year survival compared to 19 months and 70% 1-
year survival for those with classical subtype tumors (p=0.007, Fig. 3b). All cell lines 
assayed in this study (p < 0.001), as well as a majority of metastatic samples (p = 0.002), 
were classified as “basal-like”, suggesting that cell line models represent only one subset of 
PDAC. These subtypes as well as their prognostic value were independently validated within 
the recently published International Cancer Genome Consortium (ICGC) PDAC microarray 
data set (Fig. 3c, d)28. Genes from the “basal-like” factor, including laminins and keratins, 
were also consistent with basal subtypes previously defined in bladder14,28,29 and breast30 
cancers (Fig. 3e-h). Interestingly, genes from our “basal-like” subtype reproduced subtype 
calls (p<0.001) in breast cancer, had prognostic value in breast cancer samples (p<0.001) 
and reproduced previous subtype calls in bladder cancer (p<0.001). Given these promising 
results, we developed a single-sample cross-platform classifier of basal-like subtype which 
was trained on our microarray, TCGA bladder, and Perou breast cancer data, with a 93% 
cross validation accuracy, and was able to classify TCGA breast cancer data with 92% 
accuracy during external validation (Supplementary Fig. 6)
Potential subtypes of PDAC have previously been described by Collisson et al.4. We used 
the published exemplar genes for “exocrine-like”, “classical”, and “quasimesenchymal” 
subtypes to cluster normal pancreas, cell lines, and primary PDAC tumors from our cohort 
(Supplementary Fig. 7a). The three previous classifications were also observed in our data, 
but did not hold prognostic power either by cluster label or by supervised classification with 
PAM31(Supplementary Fig. 7b). Furthermore, inclusion of the Collisson et al. subtypes into 
a multivariate Cox regression with our proposed tumor subtypes did not remove the 
predictive power of our subtyping (p = 0.014). By cross-referencing the genes from 
Collisson et al.'s model with our NMF model, we observed three key findings. First, 
“exocrine-like” genes overlapped with genes from our exocrine pancreas factor (17/17). 
Tumors in this cluster had expression indistinguishable from adjacent normal samples from 
our data set. Second, Collisson et al.'s “classical” genes overlapped with our “classical” 
subtype genes (20/22), for which we retain the naming convention “classical”. Third, the 
gene set associated with “quasimesenchymal” subtype appeared to be a mixed collection of 
genes from our “basal-like” tumor (6/20) and stromal subtypes (6/20). Thus, the appearance 
of stromal factors in the Collisson et al. list of “quasimesenchymal” class genes may explain 
the apparent mesenchymal-like gene expression that was observed.
“Basal-like” and “classical” tumors were found within both “normal” and “activated” stroma 
subtypes (Fig. 4a). Differential prognosis among tumor and stroma subtypes was cumulative, 
as “classical” subtype tumors with “normal” stroma subtypes (n = 24) had the lowest hazard 
ratio of 0.39, with a 95% CI of [0.21, 0.73], while the “basal-like” subtype tumors with 
“activated” stroma subtypes (n = 26) had the highest hazard ratio of 2.28 with a 95% CI of 
[1.34, 3.87] (Fig. 4b). In a multivariate Cox regression model which included tumor 
subtypes, stromal subtypes, and clinical variables (gender, race, T stage, N stage, margin 
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status, adjuvant therapy, histological grade, and age), both classifications were 
independently associated with survival (stroma subtypes: p = 0.037, tumor subtypes: p = 
0.003).
Although basal-like subtype tumors have a worse prognosis, patients with basal-like subtype 
tumors showed a strong trend towards better response to adjuvant therapy (p=0.072, Fig. 
4c,d). Among basal-like subtype patients, adjuvant therapy provided a hazard ratio of 0.38, 
(95% CI of [0.14, 1.09]), while in patients with classical subtype tumors, adjuvant therapy is 
associated with a hazard ratio of only 0.76 (95% CI [0.40, 1.43]). In our cohort, there was no 
association of most clinical variables (race, gender, T stage, N stage, differentiation, tumor 
cellularity) with survival, although positive nodal status trended towards significance, and 
positive margin status was significantly associated with worse survival (Table 1). Table 2 
shows two-way associations of all subtype calls with clinical and pathological information 
from our cohort of PDAC patients. We found no association of tumor or stroma subtype with 
standard clinical or pathological variables, with the notable exception of mucinous features.
Tumor-specific subtypes in patient-derived xenografts
To assess the tumor or stromal specificity of our signatures, we performed RNAseq on a 
group of 37 PDX tumors. PDX tumors are composed of human tumor cells surrounded by 
mouse stroma (Supplementary Fig. 8)29. Genes from both of our tumor signatures were 
expressed as human transcripts, whereas genes from both of our stromal signatures were 
expressed as mouse transcripts (Fig. 2d, Supplementary Fig. 9a). Furthermore, we found that 
PDX RNAseq expression divided PDX into both classical and basal-like groupings 
(Supplementary Fig. 9b) while predominantly expressing an activated stromal signature 
(Fig. 2d). We found that while tumor-specific subtype was not predictive of graft success 
(Fig. 5a), patient tumors with an activated stroma subtype had significantly higher graft 
success rates than those with normal stroma subtype or low amounts of stroma (Fig. 5b) 
(p=0.019). Basal-like subtype tumors also exhibited faster growth rates than classical tumors 
(p=0.032) as measured by the length of time that tumors took to grow to 200 mm3 (TT200, 
Fig. 5c-d), a previously used metric for PDX growth30. Retrospective analysis of patients 
who had matched PDX tumors found that a shorter TT200 was associated with an 
unfavorable recurrence-free survival (p=0.035, Fig. 5e), suggesting that PDX tumor growth 
rate may reflect patient biology.
We also measured both mouse and human-specific expression of the Collisson et al. genes in 
our PDX models. We found that while genes from the “classical” subtype were expressed by 
human cells in PDX, “quasimesenchymal” transcripts were expressed by a mixture of 
human and mouse cells, and “exocrine-like” transcripts were infrequently expressed 
(Supplementary Fig. 7c). This supports our hypothesis that while the “classical” subtype is a 
bona fide group, the “quasimesenchymal” subtype is partially driven by non-tumor 
contributions of stroma and the “exocrine-like” subtype by normal pancreas.
KRAS codon mutations, tumor-specific subtypes, and race
Studies of KRAS codon mutations have demonstrated that different codon mutations may 
have differential functions31,32 and in some clinical studies, have been shown to be 
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associated with differential outcome. Because PDX tumors are enriched for human-specific 
tumor cells, we evaluated KRAS codon mutations in our PDX cohort using manually 
curated RNAseq data. While the overall frequency of KRAS codon mutations was similar to 
a recent study of PDAC7, we noted that the KRAS G12D mutation was significantly 
overrepresented in our basal-like subtype while G12V was isolated to the classical subtype 
(Figure 5f, p=0.030). Furthermore, we found an overrepresentation of KRAS G12V 
mutations in African Americans (Figure 5g, p<0.001). In contrast to basal-like breast 
cancers which occur most frequently in African American women and have a worse 
prognosis33, African American patients in our cohort tended to have mainly classical 
subtype tumors (13 vs 2). We found that similar to other cancers, African Americans had a 
worse prognosis after adjusting for tumor subtype (Figure 4e, p=0.017). African American 
patients with classical subtype tumors had a median survival of 13 months compared to 
Caucasian patients with classical subtype tumors who had a median survival of 19 months.
Other commonly mutated genes and altered pathways in PDAC
Previously, loss of SMAD4 has been shown to promote tumor growth34,35. We found that, 
similar to previous PDX studies of PDAC, loss of SMAD4 was associated with graft success 
in PDX models36 (Fig. 5h, Supplementary Fig. 10, p=0.044). Furthermore, in our PDX 
cohort, we found that SMAD4 expression was significantly higher in classical compared to 
basal-like subtype PDX tumors (Fig. 5i, p=0.015), consistent with the observation that 
SMAD4 loss confers a more aggressive phenotype.
Using mutation, genomic subtype3, and gene expression28 data from publically available 
ICGC data in which we show recapitulation of our subtypes and prognosis, we evaluated 
significantly mutated genes and pathways in PDAC, including ones recently identified 
through whole-exome sequencing of microdissected primary PDAC tumors1-3,7. We found 
no significant associations between our expression subtypes and these mutationally altered 
pathways, i.e. TGFβ, RB, NOTCH, CTNNB1, SWI/SNF, and DNA repair (Supplementary 
Fig. 11). Furthermore, we found no overlap between our subtypes and recently identified 
genomic subtypes, or response to platinum therapy3. Consistent with this, a recent 
comprehensive study of somatic mutations in PDAC long-term survivors suggested that 
somatic mutations alone will not be sufficient to explain clinical outcome37.
Given the overlap of our classical subtype with that of Collisson et al.5, it was not surprising 
to find that our classical subtype was also enriched for genes associated with GATA6 
overexpression38 (Supplementary Fig. 12a, Fig 4a). GATA6 has been found to promote 
epithelial cell differentiation38,39. This prompted us to perform a more detailed histological 
markers of differentiation in our samples and found that samples with greater than 10% 
extracellular mucin, a marker of differentiation, comprised mostly of classical subtype 
tumors (88.5%, n=23) compared to only 11.5% (n=3) of basal-like subtype tumors 
(Supplementary Fig. 13, p=0.042, Table 2). Consistent with the increased presence of 
extracellular mucin, our classical subtype was enriched for genes upregulated in mucinous 
ovarian cancer (Supplementary Fig. 12b, WAMAUNYOKOLI_OVARIAN 
CANCER_GRADES_1_2_UP40). Interestingly, our basal-like subtype was enriched for 
genes related to KRAS activation and STK11 loss in a lung cancer mouse model where 
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STK11-deficient tumors demonstrated shorter latency and more frequent metastasis41 
(Supplementary Fig. 12c). We found one sample with STK11 inactivation in the ICGC data; 
this sample was a basal-like subtype (Supplementary Fig. 11). Notably, our subtypes were 
not associated with other known signaling pathways in PDAC, including Fanconi anemia, 
DNA repair, chromatin remodeling, beta-catenin, RB, ARF, G1 (Fig. 4a). However, all of 
these pathways except for beta-catenin were considerably differentially expressed in cell 
lines compared to patient tumors, suggesting that gene expression in cell lines may be a 
deceptive representation of most tumors.
Low intra-patient heterogeneity in tumor-specific genes
We expect that only a subset of genes are relevant to the question of intra- and inter-patient 
heterogeneity in PDAC. Many methods exist to pre-select genes for supervised analysis32, 
but selection of the most differentially expressed genes is a common preprocessing step 
during unsupervised analysis33. When clustering matched samples of metastatic and primary 
lesions using the 50 most differentially expressed genes among all matched samples, 
samples separated primarily by organ site instead of by patient (Fig. 6a, c). In contrast, when 
considering 25 top ranked exemplar genes each from the “basal-like” and “classical” factors, 
samples from the same patient clustered closer together, and were less dependent of organ 
site (Fig. 6b, d). This is further illustrated in a focused analysis of two patients (Fig. 6), 
whose tumor samples appear patient-specific when considering our tumor subtype gene list, 
but cluster by site when considering differentially expressed genes. Overall, we found that 
our tumor subtype gene list showed higher similarity (mean Pearson's ρ=0.53) between all 
other samples from the same patient than did the differentially expressed gene list (ρ=0.32, t-
test p<0.001). Furthermore, our tumor subtype gene list produced much lower similarity 
among all other samples from the same organ site across different patients (ρ = 0.04) than 
the differentially expressed gene list (ρ=0.34, p<0.001). This observed similarity of tumor 
gene expression among tumors within the same patient suggests overall high inter-patient 
tumor heterogeneity and low heterogeneity between primary and metastatic sites. However, 
we did observe examples of intra-patient heterogeneity between metastatic sites. For 
example, lung metastases, even those from patients with “basal-like” tumors in other 
locations, clustered exclusively with the “classical” tumors, suggesting that some intra-
patient heterogeneity may exist among metastatic sites, and supporting the previously 
reported divergent patterns of failure in PDAC34.
Discussion
Our study represents the largest investigation of primary and metastatic PDAC gene 
expression to date. We have used NMF to identify novel prognostic subtypes of PDAC 
which may have been previously obscured by confounding normal and stromal tissue. Our 
identification of normal-, tumor-, and stroma-specific gene expression signatures is 
supported by both their overlap with previously identified gene lists and their expression in 
appropriate tissue types. Our tumor subtypes are further supported by their relationship to 
previously identified basal tumor subtypes in breast and bladder cancers and their prognostic 
relevance in external cohorts. Our findings of two different stroma subtypes may help 
explain the differential effects of stroma previously seen in preclinical models.
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Tumor and stroma specific gene expression classified PDAC into four distinct subtypes with 
prognostic relevance. The orthogonal nature of tumor- and stroma-specific subtypes suggest 
an important interplay in patient tumors that will need to be taken into account as stroma and 
immune modulating therapies are studied. In our cohort, patients with basal-like tumors 
appeared to derive more benefit from adjuvant therapy. Whether basal-like and classical 
subtypes may be associated with response to specific therapies will need to be studied 
further as more effective therapies become available. One challenge will be defining 
preclinical model systems that recapitulate these subtypes as our results suggest that 
traditional cell lines are lacking in the classical subtype. Although we demonstrate that PDX 
models recapitulate tumor-specific subtypes, these models alone may not be sufficient due to 
either the lack of human stroma or overrepresentation of the activated stroma subtype in the 
tumors that are successfully grafted. Thus more detailed characterization of genetically 
engineered mouse models of PDAC models will be needed to determine which models best 
reflect both our tumor- and stroma-specific subtypes.
Recent exome sequencing studies have confirmed commonly mutated genes in PDAC but 
have not uncovered mutations that clearly confer survival differences2,3,7. In fact, exome 
sequencing of a cohort of very long-term survivors of PDAC37 found no differences in 
somatic mutations to explain the improved biology of tumors from these rare patients 
compared to the majority of patients with PDAC, suggesting that examining somatic 
mutations alone may not be sufficient to understand the biological and clinical differences in 
PDAC tumors. Furthermore exome sequencing studies and studies of microdissected 
samples are limited to the tumor compartment and overlook the stroma compartment which 
has been shown to be biologically critical in PDAC, with both tumor-promoting and tumor-
inhibiting effects. Our results suggest that RNA subtypes may better capture the molecular 
landscape of PDAC and its reflection on patient outcome. We hypothesize that our RNA 
subtypes may reflect the broad effect of somatic mutations while also capturing the 
importance of the neoplastic stroma.
These results provide new insight into the molecular composition of PDAC which may be 
used for precision medicine. Furthermore, knowledge of these subtypes and their prognostic 
value may provide decision support in a clinical setting where the choice and timing of 
therapies is critical.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Successful Deconvolution of Normal Tissue with NMF. (a) Cartoon depicting the major cell 
types in primary tumor and liver metastasis samples. (b) (above) Overlap of sample types 
(solid colors) with factor weights (grayscale heat maps), and (below) heat maps of five 
exemplar genes for all tumors and adjacent normal tissues. Gene expression shown in the 
heat map has been Z-normalized. (c) Box and whiskers plots showing median, quartiles, and 
range comparing NMF factor weights across tissue types and corresponding t-test result. (d) 
Percent tumor cellularity versus NMF liver factor weight, and NMF basal tumor factor 
weight for metastases to the liver and adjacent liver samples. Linear regression lines are 
shown in red along with corresponding statistics.
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Dual action of stroma is described by distinct gene expression patterns which are not 
expressed in cell lines. (a) Consensus clustered heat map of UNC primary tumor samples, 
metastases, and cell lines using genes from stromal factors. Samples clustered into 3 groups, 
describing samples with activated stroma, normal stroma, and samples with low or absent 
stromal gene expression. (b) Kaplan-Meier survival analysis of resected PDAC patients from 
the activated and normal stromal clusters shows that samples in the activated stroma group 
have worse prognosis, with a hazard ratio of 1.94 (CI = [1.11,3.37], p = 0.019). (c) Gene 
expression of stromal signatures are overexpressed in CAFs as compared to tumor cell lines. 
(d) Genes from both stromal signatures are specifically overexpressed by the mouse stroma 
in PDX tumors, and not expressed by the human tumor cells.
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Tumor specific gene expression suggests two subtypes of PDAC with similarities to other 
tumor types. (a) Consensus clustered heat map of primary tumors, metastatic tumors, and 
cell line models of PDAC using correlation as the underlying distance function shows two 
subtypes of PDAC. (b) Kaplan-Meier survival analysis of resected primary patients from 
each tumor subtype (36 basal-like, 89 classical) in a shows differential prognosis among 
subtypes with a hazard ratio of 1.89, and a 95% CI of [1.19, 3.02]. (c) Consensus clustered 
heat map of tumors in the ICGC PDAC cohort split by basal and classical factor gene 
expression into basal-like (n=56) and classical (n=47) tumors. (d) Basal-like tumors in the 
ICGC data set has a hazard ratio of 2.11, with a 95% CI of [1.14, 3.89]. Median follow up 
was 20 months (e) Consensus clustered heat map of TCGA Bladder cancer samples split by 
basal and classical factor gene expression into basal-like (n=128) and classical-like (n=95) 
tumors strongly agrees with BASE47 basal calls shown above the heat map. (f) Subtyping in 
the TCGA BLCA data set had a hazard ratio of 1.43, with a 95% CI of [0.84, 2.42] (g) 
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Consensus clustered heat map of the Perou breast cancer data set as split by basal factor 
genes (n=72 basal-like, n=223 not basal) strongly agrees with the division of samples into 
previously published basal and non-basal subtypes. (h) Basal-like breast cancer, as defined 
by our labeling, had a hazard ratio of 3.52, with a 95% CI of [1.94, 6.38].
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Multivariate survival analysis of tumor and stromal subtypes. (a) Heat map of tumor samples 
using 25 genes from each of the tumor and stromal factors, with samples sorted horizontally 
by classification. Signature scores for selected gene sets appear above for each sample. (b) 
Combined Kaplan-Meier survival analysis of resected primary patients from basal-like or 
classical tumor types and normal or activated stroma subtypes with differential survival (p < 
0.001 log-rank test). Differential prognosis among subtypes shows complementarity. 
Classical tumors with normal stroma subtypes (n=24) had the lowest hazard ratio of 0.39, 
and a 95% CI of [0.21, 0.73], while basal-like tumors with activated stroma subtypes (n=26) 
had the highest hazard ratio of 2.28 with a 95% CI of [1.34, 3.87]. (c) Kaplan-Meir survival 
analysis shows that patients with classical subtype tumors show less response to adjuvant 
therapy (HR = 0.76, 95% CI [0.40, 1.43]) compared to (d) basal-like tumors (HR of 0.38, 
and a 95% CI of [0.14, 1.09]). (e) Kaplan-Meir survival analysis shows that African-
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Americans have worse overall survival in both basal-like and classical subtypes, with a 
Hazard ratio of 2.28 and a 95% CI of [1.16,4.5].
Moffitt et al. Page 18














Associations between tumor and stroma subtypes, PDX tumors, KRAS mutations and 
SMAD4 expression. (a) Tumor subtype was not associated with PDX graft success rate 
(p=0.417). (b) Activated stromal subtype samples engraft with higher success rates than low 
or normal stromal subtype samples (p=0.019) (c) Basal-like tumor subtype PDX reach 200 
mm3 faster than classical subtype PDX (p=0.032). (d) PDX from samples with activated 
stroma subtype or normal stroma subtype do not have significantly different times to reach 
200 mm3 (p=0.170). (e) PDX tumors with faster growth rates were associated with earlier 
recurrences in patients (HR = 0.31, 95% CI [0.10, 0.92]. (f) KRAS mutation type is not 
uniformly distributed among race or subtype. KRAS G12D mutations are more prevalent in 
basal-like subtype tumors than classical tumors (p=0.030). (g) African Americans have more 
G12V mutations, while Caucasians have more G12D mutations (p<0.001). (h) SMAD4 
staining in primary tumors is predictive of successful PDX engraftment (p=0.044). (i) Basal-
like subtype PDX exhibit weaker SMAD4 staining than classical subtype PDX (p=0.015).
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Overcoming tumor cellularity reveals true heterogeneity among matched primary and 
metastatic sites. (a) Sample-sample correlations of matched primary and metastatic tumors 
using the 50 most differentially expressed genes across all samples (“DE50”) causes samples 
to group by organ location. (b) Sample-sample correlations using 25 genes each from 
classical and basal-like tumor lists (”T50”) caused samples to cluster instead by tumor 
subtype and patient of origin. (c) Correlation of samples within the same patient is higher 
when using T50 genes than when using DE50 genes. (d) Correlation of samples originating 
in the same organ was higher when using DE50 than when using T50. (e) Clustering of 
multiple samples from two patients using the DE50 divides samples by organ. Genes 
expressed highly in lung and liver tissue are noted with brackets. Clustering of the same 
samples using T50 genes separates samples by patient. Brackets note genes which 
differentiate the two patients. A diagram of sampled locations for these patients indicated by 
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concentric circles, illustrating how samples simultaneously exhibit both patient (inner color) 
and organ (outer color) specific gene expression.
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